Inogen Appoints Stanislav Glezer as Chief Technology Officer

Download as PDF

GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (NASDAQ: INGN), (“Inogen” or “the Company”), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that Stanislav Glezer, MD has been appointed to the role of Chief Technology Officer responsible for R&D and Engineering, Medical Affairs, and Regulatory Affairs. Mr. Glezer will remain an Executive Vice President of the Company.

Dr. Glezer joined Inogen in June 2021 as Executive Vice President and Chief Medical Officer bringing over 27 years of experience, including expertise in the development and commercialization of combination drug device innovations, clinical development, medical and regulatory affairs as well as market access. His leadership roles span a variety of medical technology and biotechnology firms, including Becton, Dickinson and Company, Adocia S.A., Novo Nordisk, Inc., and Sanofi S.A.

Inogen also announced that Brenton Taylor, Executive Vice President, Engineering, will be leaving the Company after a transition period ending April 1, 2022.

“Since joining Inogen as Chief Medical Officer earlier this year, Stan has made a significant impact in helping us instill clinically-informed discipline in innovation, product development practices and go-to-market strategy. In this new role, Stan’s deep background in clinical research, success in developing, commercializing, and securing access for new innovations will be vital as we drive the next phase of growth and shareholder value creation,” said Nabil Shabshab, President and Chief Executive Officer of Inogen. “On behalf of all of us at Inogen, I want to thank Brenton for the instrumental role he played in founding Inogen and being an important part of its growth journey so far. We look forward to working with him on a seamless transition of his duties over the next several months and wish him well in his future endeavors.”

Dr. Glezer said, “Since joining Inogen, my view of the tremendous opportunity that lies ahead to develop products that meaningfully improve patient outcomes has only deepened. In this expanded role, I look forward to continuing our efforts to develop an integrated innovation strategy and agenda as well as to expand our collaboration with health care practitioners and technology experts to develop clinical solutions that support patients, enhance our market position and drive value for shareholders.”

Mr. Taylor commented: “It has been a privilege to work with such a talented and dedicated team over the past 20 years to design products that have improved so many lives around the world. As part of Inogen’s founding team I am proud that Inogen has become an industry leader and I look forward to following Inogen’s continued evolution and success.”

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

We are a medical technology company offering innovative respiratory products for use in the homecare setting. We primarily develop, manufacture and market innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements with respect to the announced management and organizational changes, statements concerning or implying Inogen’s future financial performance, trends and opportunities affecting Inogen, and the ability of management personnel to contribute to the development, commercialization, and access for new innovations of Inogen’s products and technologies, expand and grow its business, and increase value for its stockholders. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks related to its announced management and organizational changes, risks arising from the possibility that Inogen will not realize anticipated revenue; risks related to the Company’s supply chain and limited availability of semiconductor chips used in its batteries and POCs or cost inflation for such components; the risks related to the COVID-19 pandemic; the impact of changes in reimbursement rates and reimbursement and regulatory policies; the possible loss of key employees, customers, or suppliers; intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Quarterly Report on Form 10-Q for the period ended June 30, 2021, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.

Investor Relations:
Ali Bauerlein
ir@inogen.net

Media:
George Parr
media@inogen.net

Source: Inogen, Inc.

Released October 12, 2021